Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C5H6NO3.Zn |
| Molecular Weight | 321.621 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Zn++].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]2CCC(=O)N2
InChI
InChIKey=OWVLYQRCCIEOPF-QHTZZOMLSA-L
InChI=1S/2C5H7NO3.Zn/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*3-;/m00./s1
DescriptionSources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htmCurator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Sources: http://www.currentscience.ac.in/Volumes/102/02/0288.pdfhttps://www.drugs.com/otc/121041/cleansing-foaming-gel-acne-pro-skin.html | https://www.ncbi.nlm.nih.gov/pubmed/25727335 | https://www.ncbi.nlm.nih.gov/pubmed/21834944 | https://www.ulprospector.com/en/na/PersonalCare/Detail/6637/223524/EcoCare-Zinclean | http://www.scalp-health.com/zinc-pca.htm
Curator's Comment: description was created based on several sources, including
http://www.cir-safety.org/sites/default/files/pca.pdf
Zinc Pidolate (Zinc PCA) is a topical skin product with purifying, astingent, anti-inflammatory, antiseptic activity. It has long been used as a cosmetic ingredient, because of its astringent and anti-microbial properties. Zinc Pidolate has also being shown to be effective against halitosis. Zinc PCA prevents the UV-induced MMP-1 production in vitro by suppressing the activation of AP-1. Zinc PCA was also able to enhance type I collagen synthesis in NHDFs, by increasing the expression of the mRNA encoding the ascorbic acid transporter SVCT2 in non-UV irradiated
NHDFs, which suggests its promising effect against not only photoaged skin but also for the simple atrophic change of intrinsic skin ageing. Zinc PCA is able to suppress sebum secretion by inhibiting 5-α reductase in hyperseborrhea, to suppress body odor by forming zinc salts with short-chain fatty acids, to suppress wrinkles by inhibiting AP-1 to and inhibit bacterial growth including acne related Propionibacterium acnes.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3271 |
|||
Target ID: P02452|||Q15176|||Q9UML6 Gene ID: 1277.0 Gene Symbol: COL1A1 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2111421 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | CLEANSING FOAMING GEL ACNE PRO SKIN- zinc pidolate gel Approved UseLange Gel will turn into foam, during application. It will cleanse skin thoroughly without any dryness effect, in order to avoid hyperseboohea phenomenon, a main cause of acne. Launch Date2012 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | EcoCare™ Zinclean Approved UseUse in anti-dandruff shampoos |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Recombinant wheat antifungal PR4 proteins expressed in Escherichia coli. | 2001 Dec |
|
| Stability and CTL-activity of P40/ELA melanoma vaccine candidate. | 2001 Sep-Dec |
|
| Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase. | 2002 Apr 15 |
|
| Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via vascular endothelial growth factor receptor signalling. | 2002 Aug 16 |
|
| Conformationally restricted TRH analogues: constraining the pyroglutamate region. | 2002 Feb |
|
| Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons. | 2002 Jul 12 |
|
| Allatostatins of the tiger prawn, Penaeus monodon (Crustacea: Penaeidea). | 2002 Jun |
|
| Two novel antifungal peptides distinct with a five-disulfide motif from the bark of Eucommia ulmoides Oliv. | 2002 Jun 19 |
|
| Pseudopeptide foldamers: the homo-oligomers of pyroglutamic acid. | 2002 Jun 3 |
|
| [Effect of a drug composition containing pyroglutamic acid and pyrrolidone on the cerebral circulation]. | 2002 May-Jun |
|
| Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors. | 2002 Nov 4 |
|
| Heterologous expression and characterization of human glutaminyl cyclase: evidence for a disulfide bond with importance for catalytic activity. | 2002 Sep 3 |
|
| Characterization and sequence of tomato 2S seed albumin: a storage protein with sequence similarities to the fruit lectin. | 2003 Apr |
|
| Pigment-epithelium-derived factor (PEDF) occurs at a physiologically relevant concentration in human blood: purification and characterization. | 2003 Aug 15 |
|
| Refolding of amphioxus insulin-like peptide: implications of a bifurcating evolution of the different folding behavior of insulin and insulin-like growth factor 1. | 2003 Aug 19 |
|
| Beta-lactams as versatile synthons for homochiral ibotenate analogues with potential for activity at glutamate receptors. | 2003 Aug 7 |
|
| Pressure/temperature combined treatments of precursors yield hormone-like peptides with pyroglutamate at the N terminus. | 2003 Dec 31 |
|
| Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana. | 2003 Feb 28 |
|
| Characterization of a new bradykinin-potentiating peptide (TmF) from Trimeresurus mucrosquamatus. | 2003 Jul |
|
| Reinvestigation of the proposed folding and self-association of the Neuropeptide Head Activator. | 2003 Mar |
|
| [Evolution of the neuroprotection concept]. | 2003 Mar-Apr |
|
| [Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism]. | 2003 May |
|
| Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation. | 2003 May |
|
| Structural characterization of native mouse zona pellucida proteins using mass spectrometry. | 2003 Sep 5 |
|
| Origin of diastereoselection in the hydrosilylation of chiral N-acyliminium intermediates derived from pyroglutamic acid. | 2004 Apr 26 |
|
| Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. | 2004 Apr 9 |
|
| Glutamine in commercial liquid nutritional products. | 2004 Aug 11 |
|
| Toward the synthesis of pyroglutamate lauroyl ester: biocatalysis versus chemical catalysis. | 2004 Feb |
|
| Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site. | 2004 Feb 10 |
|
| Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections. | 2004 Mar |
|
| Mass spectrometric analysis of posttranslational modifications of a carrot extracellular glycoprotein. | 2004 May 25 |
|
| Synthesis of (2S,3R)-[3',3',3'-2H3]-valine and (2S,3S)-4-fluorovaline. | 2004 May 7 |
|
| Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. | 2004 May-Jun |
|
| Discrepin, a new peptide of the sub-family alpha-ktx15, isolated from the scorpion Tityus discrepans irreversibly blocks K+ -channels (IA currents) of cerebellum granular cells. | 2004 Oct 15 |
|
| Alpha-tocopherol pro-vitamins: synthesis, hydrolysis and accumulation in rabbit ear skin. | 2004 Oct 19 |
|
| Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). | 2004 Sep |
|
| The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. | 2004 Sep 21 |
|
| Mass spectrometry analysis of recombinant human ZP3 expressed in glycosylation-deficient CHO cells. | 2004 Sep 28 |
|
| A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition. | 2005 |
|
| The computer modelling of human TRH receptor, TRH and TRH-like peptides. | 2005 |
|
| Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate. | 2005 Aug 2 |
|
| Nanoparticles on the basis of highly functionalized dextrans. | 2005 Aug 3 |
|
| Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid. | 2005 Aug 7 |
|
| Recurrent high anion gap metabolic acidosis secondary to 5-oxoproline (pyroglutamic acid). | 2005 Jul |
|
| The removal of pyroglutamic acid from monoclonal antibodies without denaturation of the protein chains. | 2005 Jul 1 |
|
| CLPM: a cross-linked peptide mapping algorithm for mass spectrometric analysis. | 2005 Jul 15 |
|
| Total synthesis of pinnamine and anatoxin-a via a common intermediate. A caveat on the anatoxin-a endgame. | 2005 Jul 8 |
|
| Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme. | 2005 Sep |
|
| Synthesis of 1,3-dioxo-hexahydropyrido[1,2-c][1,3]diazepine carboxylates, a new bicyclic skeleton formed by ring expansion-RCM methodology. | 2005 Sep 21 |
|
| Thermostability and in vitro digestibility of a purified major allergen 2S albumin (Ses i 1) from white sesame seeds (Sesamum indicum L.). | 2005 Sep 25 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
11602214
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
C32PQ86DH4
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
SUB26632
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
DTXSID40935009
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
15454-75-8
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
DBSALT001565
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
100000090155
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
1426280
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
C32PQ86DH4
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY | |||
|
239-473-5
Created by
admin on Fri Dec 15 19:13:39 GMT 2023 , Edited by admin on Fri Dec 15 19:13:39 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
